Tuberculosis Diagnostics Market Outlook 2031
The global tuberculosis diagnostic market size was USD 1.93 Billion in 2022 and is projected to reach USD 3.15 Billion by 2031 register a substantial CAGR 5.6% during the forecast period, 2023-2031. due to a high increase in the number of cases and is becoming a major healthcare burden due to its highly contagious nature.
As the disease is a high burden, the government and other health agencies are largely concerned due to rapid increase in the demand for a quick diagnosis and effective treatment of the disease. Tuberculosis (TB) is a deadly bacteria-based and highly contagious infectious disease that severely affects the lungs as the bacteria spreads when individual sneezes or coughs.
Majorly, people affected with TB do not show any symptoms in general but some of the common symptoms can be fever, night sweats, and weight loss. A global report by the World Health Organization (WHO) on TB states that 9.6 billion people were estimated to be infected by the disease among which 1.5 million deaths were caused. Another WHO’s report suggests that 2.64 million cases were registered for TB in India alone.
As a result of which, governments and several health organizations are taking various initiatives to control the spread of the disease. For example, screening for the disease along with free access to diagnosis and treatment programs for TB is provided by the Revised National Tuberculosis Control Program (RNTCP) in India.
Advanced methods for diagnosis such as Interferon-gamma Release Assay (IGRA), cytokine detection assay, and serological tests, which are widely adopted during the emergency.
These tests are considered to be offering accurate results within a short period of time with the usage of a small amount of biological samples. Several diagnosis requirements are being fulfilled with the development of Point of Care (PoC) methods including TB lipoarabinomannan antigen test by Alere, Inc. and Xpert MTB/RIF assay by Cepheid. These diagnostic devices considered to be cost-effective, simple to use, and provide quick and accurate results.
Tuberculosis Diagnostics Market Trends, Drivers, Restraints, and Opportunities
- Growth in the elderly population is expected to boost the market growth as people above the age of 60 are most likely to be infected by TB.
- Rise in various initiatives taken by governments to promote the diagnosis of TB by understanding the gaps for the management of tuberculosis is a driving factor of the market.
- Increase in the investments made for research & development and product pipelines are expected to fuel the market expansion in the coming years.
- Increase in the demand for PoC in healthcare facilities along with advancements in technology is a major factor propelling the growth of the market.
- High price of diagnostics test and the low coverage of health insurance are key restraining factors hindering the market growth.
Scope of The Tuberculosis Diagnostics Market Report
The report on the global tuberculosis diagnostic market includes an assessment of the market, trends, and segments. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Tuberculosis Diagnostics Market – Global Industry Analysis, Growth, Share, Size, Trends, And Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Test Types (Diagnostic Laboratory Method, Phage Assay, Radiographic Method, Detection of Latent Infection, Nucleic Acid Testing, and Drug Resistance Detection)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
QIAGEN; F. Hoffmann-La Roche AG; Thermo Fisher Scientific Inc., Becton; Hologic Corp; bioMerieux SA; Abbott Laboratories; Alere Inc.; Dickinson and Co.; Hain Lifescience GmbH; Cepheid; and Sanofi
|
Tuberculosis Diagnostics Market Segment Insights
Nucleic Acid Testing & Detection of Latent Infection Segment is Expected to Register a Robust Growth Rate
On the basis of test types, the global tuberculosis diagnostics market is divided into diagnostic laboratory methods, phage assay, radio graphic method, detection of latent infection, nucleic acid testing, and drug resistance detection. The diagnostic laboratory method segment held a key share of the market in 2019 owing to an increase in the incidence of TB cases and wide adoption of the testing kits for laboratory experimental purposes.
However, nucleic acid testing & detection of latent infection is expected to register a robust growth rate during the forecast period owing to their high usage as the diagnostic tools for the disease. Furthermore, drug resistance detection is anticipated to expand at a steady rate.
Asia Pacific is Estimated to Exhibit Lucrative Growth
In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. Asia Pacific held a dominant market share in 2019 and is estimated to exhibit lucrative growth during the forecast period.
According to the world report published in 2015 countries such as India, China, Bangladesh, Indonesia, and Afghanistan has the highest number of cases as a result of which various initiatives have been taken by the local government and the World Health Organization (WHO).
Some of the programs that were planned by the local health agencies are the Revised National Tuberculosis Control Program (RNTCP) in India, Infectious and Endemic Disease Control in China, and the National TB program in Afghanistan. On the other hand, Latin America and Europe are expected to attain a significant growth rate during the forecast period.
Segments
The global tuberculosis diagnostics market has been segmented on the basis of
Test Types
- Diagnostic Laboratory Method
- Phage Assay
- Radiographic Method
- Detection of Latent Infection
- Nucleic Acid Testing
- Drug Resistance Detection
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- QIAGEN
- F. Hoffmann-La Roche AG
- Thermo Fisher Scientific Inc.
- Becton
- Hologic Corp
- bioMerieux SA
- Abbott Laboratories
- Alere Inc.
- Dickinson and Co.
- Hain Lifescience GmbH
- Cepheid
- Sanofi.
Competitive Landscape
Key players competing in the global tuberculosis diagnostics market are QIAGEN; F. Hoffmann-La Roche AG; Thermo Fisher Scientific Inc., Becton; Hologic Corp; bioMerieux SA; Abbott Laboratories; Alere Inc.; Dickinson and Co.; Hain Lifescience GmbH; Cepheid; and Sanofi. Many of these players have adopted business strategies such as the launch of new products, the advancement of technologies, mergers, partnerships, and production capacity expansion to increase their market position and expand their consumer base globally. For example, Alfa Aesar was acquired by Thermo Fisher Scientific, Inc. in 2015.
Request For Customization
Enquiry Before Buying
Speak With Analyst
